Elevated PGC-1α activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS.

Cell Metabolism
Sandrine Da CruzDon W Cleveland

Abstract

The transcriptional coactivator PGC-1α induces multiple effects on muscle, including increased mitochondrial mass and activity. Amyotrophic lateral sclerosis (ALS) is a progressive, fatal, adult-onset neurodegenerative disorder characterized by selective loss of motor neurons and skeletal muscle degeneration. An early event is thought to be denervation-induced muscle atrophy accompanied by alterations in mitochondrial activity and morphology within muscle. We now report that elevation of PGC-1α levels in muscles of mice that develop fatal paralysis from an ALS-causing SOD1 mutant elevates PGC-1α-dependent pathways throughout disease course. Mitochondrial biogenesis and activity are maintained through end-stage disease, accompanied by retention of muscle function, delayed muscle atrophy, and significantly improved muscle endurance even at late disease stages. However, survival was not extended. Therefore, muscle is not a primary target of mutant SOD1-mediated toxicity, but drugs increasing PGC-1α activity in muscle represent an attractive therapy for maintaining muscle function during progression of ALS.

References

Aug 2, 2005·Cell Metabolism·Jiandie LinBruce M Spiegelman
Jun 3, 2006·Science·Séverine BoilléeDon W Cleveland
Jul 14, 2006·Neurobiology of Disease·Erika L F HolzbaurFrank S Walsh
Dec 14, 2006·Proceedings of the National Academy of Sciences of the United States of America·Timothy M MillerBrian K Kaspar
Aug 22, 2008·The Journal of Biological Chemistry·Hibiki KawamataGiovanni Manfredi
Dec 3, 2008·Cell Metabolism·Gabriella DobrowolnyAntonio Musarò
Sep 8, 2009·Experimental Neurology·Luc Dupuis
Feb 25, 2010·Journal of Receptor and Signal Transduction Research·Christoph Handschin
May 13, 2010·Human Molecular Genetics·Steve PedriniPiera Pasinelli
May 25, 2010·Mechanisms of Ageing and Development·Hibiki Kawamata, Giovanni Manfredi
Nov 17, 2010·Proceedings of the National Academy of Sciences of the United States of America·Quan LiTimothy M Miller

❮ Previous
Next ❯

Citations

Oct 3, 2012·Proceedings of the National Academy of Sciences of the United States of America·Rachel TeslaAndrew A Pieper
May 15, 2013·Human Molecular Genetics·Judith EschbachPatrick Weydt
Jun 16, 2012·The Journal of Pharmacology and Experimental Therapeutics·Ashu Johri, M Flint Beal
Nov 8, 2013·Molecular Neurobiology·O PansarasaC Cereda
May 13, 2014·Current Obesity Reports·Brian A IrvingGeorge Argyropoulos
May 6, 2014·Revue neurologique·V ProcaccioP Reynier
Mar 13, 2014·Proceedings of the National Academy of Sciences of the United States of America·Chunxing YangZuoshang Xu
Apr 2, 2014·Nature Communications·Anne-Sophie ArnoldChristoph Handschin
Dec 3, 2014·Neurochemistry International·Mariarita GalbiatiAngelo Poletti
Feb 8, 2014·Disease Models & Mechanisms·Elizabeth M MacDonaldRonald D Cohn
Jul 16, 2014·Experimental Neurology·Lindsay PoppeLudo Van Den Bosch
Aug 17, 2014·The Journal of Physiology·Jessica CannavinoMaria Antonietta Pellegrino
Feb 25, 2014·Metabolism: Clinical and Experimental·Mun Chun Chan, Zolt Arany
Dec 2, 2015·Proceedings of the National Academy of Sciences of the United States of America·Shuying SunDon W Cleveland
Nov 26, 2015·Human Molecular Genetics·Mohammad A EsmaeiliMahmoud Kiaei
Nov 14, 2012·Journal of Neuropathology and Experimental Neurology·Nadine ThauSusanne Petri
Sep 27, 2015·Biochemical and Biophysical Research Communications·Yanli XuJianzhong Zhang
Mar 15, 2016·Nature Communications·Koichi HasegawaKazuaki Yoshikawa
Nov 7, 2012·IUBMB Life·Loukia KatsouriMagdalena Sastre
Dec 12, 2012·The FEBS Journal·Antonio Musarò
Jul 24, 2015·Neurochemical Research·Nirma D Perera, Bradley J Turner
Oct 10, 2013·British Journal of Pharmacology·J C Komen, D R Thorburn
Jan 19, 2016·Brain Pathology·Jean-Philippe LoefflerJose-Luis Gonzalez De Aguilar
Jul 5, 2015·Life Sciences·Yohei TanadaTakeshi Kimura
Sep 15, 2012·Neurobiology of Disease·Aaron P RussellTakayuki Akimoto
Sep 11, 2014·Drug Discovery Today·Yongjin ZhuXin Wang
Aug 1, 2015·Translational Neurodegeneration·Zhen JiangXinglong Wang
May 3, 2015·Trends in Endocrinology and Metabolism : TEM·Jorge C CorreiaJorge L Ruas
Apr 10, 2013·Free Radical Biology & Medicine·Rajnish K Chaturvedi, M Flint Beal
Dec 3, 2013·Biochimica Et Biophysica Acta·Aaron P RussellGlenn D Wadley
May 9, 2012·Cell Metabolism·Ashu Johri, M Flint Beal
May 6, 2016·Frontiers in Cellular Neuroscience·Angelique PasquinelliGabriele Siciliano
Mar 19, 2014·Drug Discovery Today·Kristoffer Svensson, Christoph Handschin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating genetic alterations in this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.